摘要
糖尿病心肌病(DCM)是一种以心肌细胞肥大、凋亡和纤维化的进展为主要特征的特殊心肌病,表现为心肌结构和功能的异常。与DCM潜在的病理生理变化相关的分子机制包括丝裂原激活的蛋白激酶、过氧化物酶体增殖物激活受体、5型磷酸二酯酶、核转录因子红系2相关因子、氧连接的N-乙酰葡糖胺、蛋白激酶C、小分子核糖核酸和外泌体通路的异常等,这些信号通路有望作为治疗的潜在靶点。现对DCM在分子通路方面的机制及潜在治疗策略的最新进展进行综述,以期为DCM的治疗提供一定的指导。
Diabetic cardiomyopathy(DCM) is a special cardiomyopathy characterized by hypertrophy, apoptosis and the development of fibrosis, which is characterized by abnormal myocardial structure and function.Molecular mechanisms associated with potential pathophysiological changes in DCM include abnormalities of AMPK,PPAR,PDE5,Nrf2,O-GlcNAc, PKC,microRNA and exosome pathways, which are expected to serve as potential therapeutic targets.This article reviews the latest progress of molecular pathways and potential therapeutic strategies in DCM,in order to provide some guidance for the treatment of DCM.
作者
李艳鹏
马依彤
LI Yanpeng;MA Yitong(Heart Center of The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
出处
《心血管病学进展》
CAS
2022年第9期795-798,共4页
Advances in Cardiovascular Diseases
基金
新疆维吾尔自治区重点实验室开放课题(2020D04008)。
关键词
糖尿病心肌病
信号通路
靶向治疗
Diabetic cardiomyopathy
Signal pathway
Targeted therapy
